Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT06798948

Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial

Led by Li Lab,MD · Updated on 2025-04-23

100

Participants Needed

2

Research Sites

147 weeks

Total Duration

On this page

Sponsors

L

Li Lab,MD

Lead Sponsor

X

Xin Hua Hospital of Zhejiang Province

Collaborating Sponsor

AI-Summary

What this Trial Is About

Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals. With the prevalence of obesity and type 2 diabetes, the morbidity and incidence of MAFLD have been increasing globally, particularly in China. MAFLD and metabolic syndrome as well as type 2 diabetes are mutually causal, jointly promoting the incidence of atherosclerotic cardiovascular disease, chronic kidney disease, liver decompensation, and malignant tumors such as hepatocellular carcinoma. MAFLD has become an increasingly severe public health issue in China. Effective clinical interventions for MAFLD patients are of great public health significance for the prevention of terminal diseases. Cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra are traditional Chinese medicinal herbs that have demonstrated significant effectiveness in improving metabolic diseases. Cynara scolymus contains polyphenols, flavonoids, terpenes, and other substances, possessing antioxidant, anti-aging, anti-tumor, anti-microbial, antihypertensive, and kidney-tonifying properties. Silybum marianum belongs to the Compositae family and has the effects of clearing heat and detoxifying, soothing the liver, and promoting bile flow. The active ingredient of silybum marianum is silymarin, a flavonoid compound, which has antioxidant and anti-hepatic fibrotic effects, protecting hepatocytes from damage by free radicals and promoting hepatocyte regeneration and repair. Curcuma longa is a flowering plant of the zingiberaceae family, and its active ingredient curcumin has multiple functional properties such as anti-tumor, anti-inflammatory, hypoglycemic, and antioxidant activities. Glycyrrhiza glabra is one of the commonly used medicinal plants, possessing the effects of clearing heat and detoxifying, tonifying the spleen and benefiting qi, nourishing the lungs, and resolving phlegm. Its main active ingredients include triterpenoid saponins, flavonoids, and polysaccharides, which exhibit various pharmacological effects such as antioxidant, immunoregulatory, antiviral, and anti-tumor activities. At the human population level, there is currently no research on the combined intervention of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra in patients with MAFLD. Therefore, this study intends to conduct a randomized controlled double-blind trial to explore the effects of the combined application of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra on liver function, liver fat content, glucose and lipid metabolism, and other aspects in patients with MAFLD, in order to clarify the health improvement effects of this combined intervention in patients with MAFLD and provide population-based evidence and strategies for health promotion in this patient group.

CONDITIONS

Official Title

Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with metabolic-associated fatty liver disease with mild to moderate fatty liver
  • Aged between 18 and 65 years, any gender
  • No use of liver-protecting medications in the past 3 months
  • Voluntarily agree and sign informed consent to participate in all study visits and treatments
Not Eligible

You will not qualify if you...

  • Excessive alcohol consumption or unclear alcohol use in the past 12 months (≥210g/week for males, ≥140g/week for females)
  • Pregnant, breastfeeding, or planning pregnancy within 3 months
  • Known allergies or reactions to ingredients in the study products
  • Previous or current use of liver-protecting products containing study herbs
  • Other liver diseases like autoimmune liver disease, viral hepatitis, liver fibrosis, cirrhosis, drug-induced liver disease, Wilson's disease
  • Current treatment for obesity, hypertension, or diabetes with related medications
  • Diseases causing fatty liver such as total parenteral nutrition or congenital lipoatrophic diabetes
  • Long-term use of drugs known to cause fatty liver or inflammation (e.g., amiodarone, methotrexate, tamoxifen, glucocorticoids)
  • Severe cardiovascular, cerebrovascular diseases, or kidney failure
  • Unstable weight or metabolism in 6-8 weeks before randomization (weight change >5% or rapid loss >1.6 kg/week)
  • Cancer history in past 5 years except localized skin basal cell carcinoma
  • Immunosuppression or immunodeficiency disorders, or current immunosuppressive treatment
  • Chronic diseases like asthma, epilepsy, thyroid disorders or related treatments
  • History of drug abuse
  • Antibiotic use in past month
  • Participation in other intervention studies in past 3 months or receiving other treatments during study
  • Other factors judged by researchers to affect participation or follow-up, such as unstable living or work environment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The Second Affiliated Hospital of Zhejiang Chinese Medical University

Hangzhou, Select..., China, 310053

Actively Recruiting

2

Zhejiang Xinhua Hospital

Hangzhou, Zhejiang, China, 310005

Actively Recruiting

Loading map...

Research Team

Q

Qingling Huang

CONTACT

K

Kaixin Pan

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here